This differs from GLP-1 medications, where appetite suppression reverses within days of stopping
A., Bozaykut, A., & zdemir, G
If youre deciding rather than stacking, the rough guidelines most clinicians use are: BPC-157 alone patients whose primary issue is gut inflammation, inflammatory bowel conditions, NSAID-induced stomach damage, or broader systemic inflammation where the gut is the focal point
Easy to use
Tirzepatide activates GLP-1 and GIP receptors to reduce appetite and slow gastric emptying, creating a caloric deficit through reduced intake
If dietary sources are insufficient, however, a doctor may recommend supplementation through pills or injections, depending on the cause of the deficiency.